Expertise in
42
conditions

Dr. Michael D. Kohen

Allergy and Immunology | Rheumatology
Michael D. Kohen MD PA
709 N Clyde Morris Blvd, 
Daytona Beach, FL 
Accepting New Patients
Offers Telehealth
Expertise in
42
conditions
Michael D. Kohen MD PA
709 N Clyde Morris Blvd, 
Daytona Beach, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Kohen is an Allergy and Immunologist and a Rheumatologist in Daytona Beach, Florida. Dr. Kohen is highly rated in 42 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Grass Allergy, Psoriasis, and Juvenile Temporal Arteritis. Dr. Kohen is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Allergy and Immunology
Rheumatology
Licenses
Allergy & Immunology in FL
Hospital Affiliations
Halifax Health Medical Center
Adventhealth Daytona Beach
Adventhealth New Smyrna Beach
Florida Hospital Flagler
Adventhealth Deland
Languages Spoken
English
Cantonese
Mandarin
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Dominion National
  • MEDICARE PDP
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Florida Health
  • HMO
  • POS
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 28 Less Insurance Carriers -

Locations

MICHAEL D. KOHEN MD PA
709 N Clyde Morris Blvd, Daytona Beach, FL 32114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drug: TAK-079
Study Phase: Phase 1
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Journal: Arthritis research & therapy
Published: August 17, 2011
Similar Doctors
Expertise in
15
conditions
Dr. Yong H. Tsai
Rheumatology | Allergy and Immunology
Expertise in
15
conditions
Dr. Yong H. Tsai
Rheumatology | Allergy and Immunology
1893 N Clyde Morris Blvd, Suite 110, 
Daytona Beach, FL 
 (2.8 miles away)
386-676-0307
Languages Spoken:
English, French, Mandarin, Spanish, Taiwanese, Tigrinya
See accepted insurances
Accepting New Patients
Offers Telehealth

Yong Tsai is a Rheumatologist and an Allergy and Immunologist in Daytona Beach, Florida. Dr. Tsai is highly rated in 15 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, and Postmenopausal Osteoporosis. Dr. Tsai is currently accepting new patients.

Expertise in
17
conditions
Dr. Vinicius C. Costa-Diniz
Rheumatology
Expertise in
17
conditions
Dr. Vinicius C. Costa-Diniz
Rheumatology

Michael D. Kohen MD PA

709 N Clyde Morris Blvd, 
Daytona Beach, FL 
 (0.1 miles away)
386-252-1632
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vinicius Costa-Diniz is a Rheumatologist in Daytona Beach, Florida. Dr. Costa-Diniz is highly rated in 17 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Juvenile Temporal Arteritis, Giant Cell Arteritis (GCA), and Necrotizing Vasculitis. Dr. Costa-Diniz is currently accepting new patients.

Expertise in
13
conditions
Dr. Maria V. Vintimilla
Rheumatology
Expertise in
13
conditions
Dr. Maria V. Vintimilla
Rheumatology
1055 N Dixie Fwy, Suite 1, 
New Smyrna Beach, FL 
 (14.0 miles away)
386-423-0505
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Maria Vintimilla is a Rheumatologist in New Smyrna Beach, Florida. Dr. Vintimilla is highly rated in 13 conditions, according to our data. Her top areas of expertise are Rheumatoid Arthritis (RA), Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, and MASS Phenotype. Dr. Vintimilla is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kohen's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 32 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile